Examination of 75 patients showed that the activity of bcl-2 in a tumour was a strong indicator that a patient would respond well to a drug called tamoxifen.
"I don't think that either the people who discovered BCL-2 in the late '80s or the people at Genta back in 1992 knew what they were picking up, " says Warrell.
Genasense, which is used in combination with chemotherapy, works by targeting a key "cell suicide" gene called bcl-2 and then inducing cancer cells to kill themselves.